Fuda Cancer Hospital
The Wertheim-Meigs operation in China typically costs between $17,500 and $31,500. Total expenses depend on the surgical approach, clinic accreditation, and the city. In the US, similar procedures cost around $52,500 on average. Patients can find savings of approximately 53%. Common inclusions involve surgical fees, local anesthesia or general sedation, and inpatient hospital stays.
Bookimed Expert Insight: China offers high-value oncology care through specialized centers like Fuda Cancer Hospital. This JCI-accredited facility has treated over 30,000 international patients. It focuses on minimally invasive therapies instead of standard chemotherapy. Choosing Guangzhou-based specialists allows access to advanced technologies like NanoKnife and cryosurgery. These options provide significant value for patients with complex or late-stage oncology cases.
| China | Turkey | Austria | |
| The Wertheim-Meigs operation | from $17,500 | from $12,500 | from $22,000 |
No hidden fees – just official clinic prices. Pay at the clinic for The Wertheim-Meigs operation upon arrival and use a flexible installment plan if needed.
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in The Wertheim-Meigs operation and have the necessary licenses to serve international patients worldwide.
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your The Wertheim-Meigs operation journey.
Day 1
Day 2
Day 3
Day 4
Week 1
Week 2
Week 3 - 6
Week 7 - 10
Week 12
Please note that the timeline and processes can vary depending on individual cases and the surgeon"s recommendations.
Chief physician and professor. Grade 1 Expert at the Cancer Center, West China Hospital, Sichuan University (ranked No. 2 in China). Completed a postdoctoral fellowship in interventional radiology at the Chinese PLA General Hospital. Leads multidisciplinary team (MDT) care for complex tumors. Expert in minimally invasive interventional oncology for liver, lung, and pancreatic cancers.
Accreditations: Council Member, WATA. Member of CACA and CMDA committees on intervention, ablation, radioactive seeds, and pain. In 2023, inaugural director member, Palliative Care Committee, Sichuan MDA. Editorial board member of the Chinese Journal of Interventional Imaging and Therapy. Editorial board member of the Chinese Journal of Pain Medicine.
Leads 2 provincial S&T projects and 2 NSFC projects. Has 40+ papers, with 30+ as first or corresponding author. Highest impact factor: 10.73. Hepatocellular carcinoma (HCC) cohort: TACE + lenvatinib vs TACE + sorafenib. OS 18.97 vs 10.77 months. PFS 10.6 vs 5.4 months. ORR 66.8% vs 33.3%.
Professor Xiao Yueyong is Chief Physician in the Department of Radiological Diagnosis at the Chinese PLA General Hospital. He is a leading expert in minimally invasive interventional oncology. He serves as the inaugural President of WATA (2025–). He is President of the International (2020–) and Asian (2012–) Societies of Cryotherapy. He is also Deputy Head of the NHC Expert Group on tumour ablation regulations (2009–).
He has performed over 100,000 CT/MRI‑guided minimally invasive procedures. His work covers chemical ablation, RFA, MWA, cryoablation, and NanoKnife (IRE). He introduced and advanced NanoKnife ablation in China. He led the first national standards for tumour cryoablation and NanoKnife.
Honors include the National Special Contribution Award (Lifetime Honorary). He received First Prize from the Chinese Medicine Education Association (2021). He received two Second Prizes for Military Medical Achievements (2016, 2018) and two Second Prizes from the China Anti‑Cancer Association (2019, 2022). He was named Asian Ablation Master. His research record includes 13 Chinese patents. He is the principal investigator for four NSFC projects and one MOST subject. He has published over 200 papers, with over 110 as first or corresponding author and over 40 in SCI journals. He has led over 10 ablation guidelines or consensus statements.
Dr. Niu Lizhi is the President and chief surgeon at Fuda Cancer Hospital in Guangzhou. He has performed nearly 10,000 cryosurgeries and 500 NanoKnife procedures. Dr. Niu specializes in minimally invasive oncology for lung, pancreatic, and liver cancers. He treats patients ranging from early childhood through age 94.